Follows survival and treatment sequences in people with chronic lymphocytic leukemia
Observes long-term survival in adults with chronic lymphocytic leukemia after first-line treatment.
Plain-language title generated from the registry record
Registry title: A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
Key facts
- Where
- Cologne and Ulm, GermanySee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06792994, who can take part
Where in Germany
- University Hospital CologneCologne, GermanyTaking people
- Universitätsklinikum UlmUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- German CLL Study Group
- Trial code
- NCT06792994
- Record updated
- 30 April 2026
- Original description
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.Read full original descriptionShow less
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.
Inclusion: • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB); Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion); First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17); Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial; Subjects are willing and able to comply with procedures required in this protocol.
Exclusion: • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17); Subjects with legal incapacity; Subjects who are institutionalized by regulatory or court order; Subjects who are in dependence to the sponsor or the investigator.